A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25 -hydroxy vitamin D and 1, 25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25 -hydroxy vitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1, 25-dihydroxyvitamin D are increased to or maintained within a patients normal historical physiological range for 1, 25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25- hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1, 25-dihydroxyvitamin D are maintained in the patients normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25- hydroxyvitamin D during treatment comprises predominantly 25 -hydroxy vitamin D3, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D3 for 25 -hydroxy vitamin D repletion and/or maintenanceLinvention concerne un procédé de traitement dune élévation anormale des taux sanguins diPTH en augmentant ou en maintenant des concentrations sanguines de 25-hydroxy vitamine D et de 1,25-dihydroxy vitamine D chez un patient en administrant, selon les besoins, des thérapies de réplétion à la fois de Vitamine D et de remplacement hormonal de vitamine D. Les concentrations sanguines de la 25-hydroxy vitamine D sont augmentées et maintenues à 30 ng/ml ou moins, et les concentrations sanguines de la 1,25-dihydroxy vitamine D sont augmentées ou maintenues dans une plage physiologique historique normale pour le patient de la 1,25-dihydroxy vitamine D sans risquer une augmentation sensi
